Gene Writing – Talk Bio

Actionable Insights Powered by AI

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, gene therapy, Gene Writing, Investments, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, ARPA-H grant, CAR-T, Clinical Trials, Gene Writing, genome engineering, in vivo, Lipid Nanoparticles, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Gene Writing; in vivo CAR-T; ARPA-H grant; Regeneron partnership; TSRA-196; alpha-1 antitrypsin deficiency; Lipid Nanoparticles; in vivo genome engineering; clinical trials